ASTRO Names New Honorary Members

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

Officials from the American Society for Therapeutic Radiology and Oncology (ASTRO) have announced that Ann Barrett, md, of the University of East Anglia in the United Kingdom, and John J. Curry, of the American College of Radiology, have

Officials from the American Society for Therapeutic Radiology and Oncology (ASTRO)have announced that Ann Barrett, md, of the University of East Anglia in theUnited Kingdom, and John J. Curry, of the American College of Radiology, havebeen chosen to receive honorary memberships—the highest honor ASTRO bestowsupon distinguished cancer researchers and leaders in disciplines other thanradiation oncology, radiation physics, and radiobiology.

"Honorary membership is reserved for distinguished men and women whohave made significant contributions to the objectives of our society," saidASTRO chair David A. Larson, phd, md, facr. "I am honored to present thisaward to two outstanding individuals who, in the course of their careers, havegreatly advanced the specialty of radiation oncology."

Distinguished Honorees

Dr. Barrett was a founding member of the European Society for TherapeuticRadiology and Oncology, serving as that organization’s president from 1997 to1999. Recognized as an international authority on pediatric radiation oncology,she is presently the Foundation Chair of Oncology at the University of EastAnglia, and is working to develop that university’s new medical school.

Mr. Curry is known for a lifetime of promoting excellence in radiationtherapy and research. In 1984, he became executive director of the AmericanCollege of Radiology, and under his leadership, the organization has become apowerful voice in setting standards, and developing appropriateness guidelinesand accreditation programs for both diagnostic and therapeutic radiology.

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content